Mergers & Acquisitions Mergers & Acquisitions

Comment: Illumina-Grail review sees EU regulator weighing matters of life and death

By Natalie McNelis
  • 06 Jul 2021 07:22
  • 06 Jul 2021 07:22
Merger control doesn't usually involve matters of life and death — despite some dealmakers’ dramatic posturing — so pity the EU regulators grappling with the Illumina-Grail deal. 

On one hand, they’ve got a powerful company promising to speed an innovative, life-saving cancer test onto the EU market, perhaps years earlier tha

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Natalie McNelis

Senior Correspondent

Natalie McNelis covers mergers for MLex in Brussels. Before joining MLex in 2017, she spent 20 years as an international trade and competition lawyer in law firms including Stibbe and WilmerHale. Natalie has a BA in English from Mount Holyoke College, a JD from Harvard Law School and an LLM in EU law from KU Leuven. She is admitted to the bar in New York.

Discover MLex

Stay on top of global regulatory developments

Latest News